154 related articles for article (PubMed ID: 33048115)
21. 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis.
Mu M; Zhang Q; Zhao C; Li X; Chen Z; Sun X; Yu J
Cancer Gene Ther; 2023 Oct; 30(10):1414-1425. PubMed ID: 37558749
[TBL] [Abstract][Full Text] [Related]
22. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell.
Yang X; Wang S; Yu W; Zheng Y; Wu Y
Medicine (Baltimore); 2020 Jul; 99(27):e20944. PubMed ID: 32629699
[TBL] [Abstract][Full Text] [Related]
24. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
Weng WH; Leung WH; Pang YJ; Hsu HH
Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
[TBL] [Abstract][Full Text] [Related]
25. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
26. ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer.
Hong HJ; Shao Y; Zhang S; Yang G; Jia H; Yang X; Huang L; Li S; Aikemu B; Zhang L; Ma J; Zang L; Sun J; Zheng M
Acta Biochim Biophys Sin (Shanghai); 2022 Sep; 54(11):1671-1683. PubMed ID: 36111743
[TBL] [Abstract][Full Text] [Related]
27. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
[TBL] [Abstract][Full Text] [Related]
28. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.
Cacciola NA; Calabrese C; Malapelle U; Pellino G; De Stefano A; Sepe R; Sgariglia R; Quintavalle C; Federico A; Bianco A; Uchimura Bastos A; Milone M; Bellevicine C; Milone F; Carlomagno C; Selvaggi F; Troncone G; Fusco A; Pallante P
Mol Carcinog; 2016 May; 55(5):793-807. PubMed ID: 25917796
[TBL] [Abstract][Full Text] [Related]
29. SOX8 promotes cetuximab resistance via HGF/MET bypass pathway activation in colorectal cancer.
Piao HY; Qu JL; Liu YP
Cancer Chemother Pharmacol; 2022 Apr; 89(4):441-449. PubMed ID: 35195773
[TBL] [Abstract][Full Text] [Related]
30. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.
Johnson RM; Qu X; Lin CF; Huw LY; Venkatanarayan A; Sokol E; Ou FS; Ihuegbu N; Zill OA; Kabbarah O; Wang L; Bourgon R; de Sousa E Melo F; Bolen C; Daemen A; Venook AP; Innocenti F; Lenz HJ; Bais C
Nat Commun; 2022 Sep; 13(1):5478. PubMed ID: 36117191
[TBL] [Abstract][Full Text] [Related]
31. RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Li XX; Zheng HT; Peng JJ; Huang LY; Shi DB; Liang L; Cai SJ
Int J Clin Exp Pathol; 2014; 7(5):2729-36. PubMed ID: 24966994
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
33. Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer.
Xu X; Liu M; Peng K; Yu Y; Liu T
Clin Transl Oncol; 2023 Mar; 25(3):776-785. PubMed ID: 36609651
[TBL] [Abstract][Full Text] [Related]
34. A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF
Georgiou A; Stewart A; Vlachogiannis G; Pickard L; Valeri N; Cunningham D; Whittaker SR; Banerji U
Cell Oncol (Dordr); 2021 Oct; 44(5):1197-1206. PubMed ID: 34462871
[TBL] [Abstract][Full Text] [Related]
35. LncRNA
Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
[TBL] [Abstract][Full Text] [Related]
36. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
[TBL] [Abstract][Full Text] [Related]
37. Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
Yu C; Hong H; Lu J; Zhao X; Hu W; Zhang S; Zong Y; Mao Z; Li J; Wang M; Feng B; Sun J; Zheng M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806905. PubMed ID: 30336768
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer.
Wang L; Wei Y; Fang W; Lu C; Chen J; Cui G; Diao H
Cell Physiol Biochem; 2017; 44(3):1038-1050. PubMed ID: 29179214
[TBL] [Abstract][Full Text] [Related]
39. NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer.
Yang G; Huang L; Jia H; Aikemu B; Zhang S; Shao Y; Hong H; Yesseyeva G; Wang C; Li S; Sun J; Zheng M; Ma J
Oncogene; 2021 Oct; 40(41):5993-6006. PubMed ID: 34385595
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
